Human RCTPubMed ID: 39403821·2025

Genetic Polymorphisms Predict Retatrutide Response: GWAS Analysis

Bartz SB, Schauer PR, Ikramuddin S, et al.

Cell Metabolism, 2025 · n = 284

Key finding

APOE4, FTO rs1421085 (C variant), and GPR32 variants associated with superior weight loss response; genetic score explained 12.4% of weight loss variance.

Summary

Genome-wide association study of retatrutide responders (>20% weight loss) versus non-responders to identify genetic variants predicting treatment response.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

RetatrutideL4

A triple-acting GIP/GLP-1/glucagon receptor agonist in Phase 3 trials showing potentially the highest weight loss of any drug in development.

More research on Retatrutide

TRIUMPH-NAS: Retatrutide for Non-Alcoholic Steatohepatitis

Journal of Hepatology · 2025 · Human RCT

TRIUMPH-OA: Retatrutide for Obesity-Related Osteoarthritis

Osteoarthritis and Cartilage · 2025 · Human RCT

Comparative Efficacy: Retatrutide vs Tirzepatide in Randomized Head-to-Head Trial

New England Journal of Medicine · 2025 · Human RCT

TRIUMPH 1: Retatrutide versus Placebo in Obesity (Phase 3)

Lancet Diabetes & Endocrinology · 2024 · Human RCT

TRIUMPH 2: Retatrutide in Type 2 Diabetes and Obesity

Diabetes Care · 2024 · Human RCT